Research programme: anxiety disorder therapeutics - Johnson & JohnsonAlternative Names: JNJ 5234801; NOP modulators - Johnson & Johnson
Latest Information Update: 03 Jul 2007
At a glance
- Originator Johnson & Johnson
- Class Piperidines
- Mechanism of Action Nociceptin receptor modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Anxiety disorders
Most Recent Events
- 06 May 2004 Preclinical trials in Anxiety disorders in USA (unspecified route)